0000950170-24-029910.txt : 20240312
0000950170-24-029910.hdr.sgml : 20240312
20240312160510
ACCESSION NUMBER: 0000950170-24-029910
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240308
FILED AS OF DATE: 20240312
DATE AS OF CHANGE: 20240312
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Davis Andrew
CENTRAL INDEX KEY: 0001932525
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34620
FILM NUMBER: 24742053
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET
STREET 2: SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001446847
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 043404176
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
ownership.xml
4
X0508
4
2024-03-08
0001446847
IRONWOOD PHARMACEUTICALS INC
IRWD
0001932525
Davis Andrew
C/O IRONWOOD PHARMACEUTICALS, INC.
100 SUMMER STREET, SUITE 2300
BOSTON
MA
02110
false
true
false
false
SVP, Chief Business Officer
false
Class A Common Stock
2024-03-08
4
M
false
37120
0
A
310756
D
Performance-based Restricted Stock Unit
2024-03-08
4
M
false
37120
0
D
2026-02-28
Class A Common Stock
37120
0
D
Represents shares earned upon satisfaction of certain performance criteria associated with performance-based restricted stock units (PSUs) granted on March 8, 2023. The earned PSUs were certified on February 12, 2024, and March 7, 2024, and vested on March 8, 2024.
Each PSU represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs are earned upon the Issuer's Class A Common Stock achieving a specified price per share.
Additional PSUs may vest upon the Issuer's Class A Common Stock achieving specified prices per share beyond the previously achieved vesting targets.
/s/ Brian Tessler, Attorney-in-Fact
2024-03-12